|
|
|
Volumn 41, Issue 2, 2011, Pages 559-592
|
|
Informed by the European Union experience: what the United States can anticipate and learn from the European Union's regulatory approach to biosimilars.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BIOLOGICAL PRODUCT;
ARTICLE;
COST CONTROL;
DRUG APPROVAL;
DRUG INDUSTRY;
DRUG LABELING;
DRUG LEGISLATION;
DRUG PACKAGING;
ECONOMIC ASPECT;
ECONOMICS;
EUROPEAN UNION;
FOOD AND DRUG ADMINISTRATION;
HEALTH CARE POLICY;
HUMAN;
LEGAL ASPECT;
ORGANIZATION AND MANAGEMENT;
PATENT;
PHARMACOKINETICS;
POSTMARKETING SURVEILLANCE;
RISK MANAGEMENT;
UNITED STATES;
BIOLOGICAL PRODUCTS;
COST SAVINGS;
DRUG APPROVAL;
DRUG INDUSTRY;
DRUG LABELING;
DRUG PACKAGING;
ECONOMIC COMPETITION;
EUROPEAN UNION;
HEALTH POLICY;
HUMANS;
LEGISLATION, DRUG;
PATENTS AS TOPIC;
PRODUCT SURVEILLANCE, POSTMARKETING;
RISK MANAGEMENT;
THERAPEUTIC EQUIVALENCY;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 79960572643
PISSN: 05865964
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (6)
|
|
References (0)
|
